A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema (original) (raw)

Abstract

To compare the safety and efficacy of different doses of intravitreal triamcinolone (ivTA) in treating clinically significant diabetic macular oedema (CSMO). Methods: 63 eyes of 63 patients with CSMO and central foveal thickness (CFT) of >250 mm on optical coherence tomography were randomised to receive 4 mg (n = 23), 6 mg (n = 20) or 8 mg (n = 20) ivTA. Patients were followed up for 6 months, and changes in best-corrected visual acuity (BCVA), optical coherence tomography CFT, standardised change in macular thickness (SCMT), and side effects such as intraocular pressure and cataractogenesis were compared between the three groups. Results: After ivTA injection, improvements of BCVA and CFT occurred in all groups. The mean BCVA improvement at 6 months was significantly higher for the 8 mg group compared with the 4 mg group, with 9.9 and 3.1 improvement in letters on the Early Treatment of Diabetic Retinopathy Study chart, respectively (p = 0.047). The mean SCMT at 6 months for the 4, 6 and 8 mg groups was 28.7%, 42.3% and 60.5%, respectively (p = 0.06). The proportion of eyes with SCMT >75% at 6 months was higher in the 8 mg group, but the difference failed to reach significance (p = 0.06). Ocular hypertensive responses (.21 mm Hg) occurred in 39%, 30% and 55% of eyes in the 4, 6, and 8 mg groups, respectively (p = 0.27). Conclusions: Higher doses of ivTA may prolong the duration of visual benefit in diabetic CSMO and seemed to result in more sustained reduction in macular oedema. Further studies are warranted to investigate the optimum dose of ivTA in treating diabetic CSMO.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (19)

  1. Bakri SJ, Beer PM. Intravitreal triamcinolone injection for diabetic macular oedema: a clinical and fluorescein angiographic case series. Can J Ophthalmol 2004;39:755-60.
  2. Jonas JB, Kreissig I, Sofker A, et al. Intravitreal injection of triamcinolone for diffuse diabetic macular oedema. Arch Ophthalmol 2003;121:57-61.
  3. Jonas JB, Akkoyun I, Kreissig I, et al. Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomised study. Br J Ophthalmol 2005;89:321-6.
  4. Lam DS, Chan CK, Mohamed S, et al. Phacoemulsification with intravitreal triamcinolone in patients with cataract and coexisting diabetic macular oedema: a 6-month prospective pilot study. Eye 2005;19:885-90.
  5. Lam DS, Chan CK, Tang EW, et al. Intravitreal triamcinolone for diabetic macular oedema in Chinese patients: six-month prospective longitudinal pilot study. Clin Exp Ophthalmol 2004;32:569-72.
  6. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular oedema. Ophthalmology 2002;109:920-7.
  7. Ozkiris A, Evereklioglu C, Erkilic K, et al. Intravitreal triamcinolone acetonide injection as primary treatment for diabetic macular oedema. Eur J Ophthalmol 2004;14:543-9.
  8. Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 2004;111:2044-9.
  9. 9 Jonas JB, Degenring R, Kreissig I, et al. Safety of intravitreal high-dose reinjections of triamcinolone acetonide. Am J Ophthalmol 2004;138:1054-5.
  10. Ozkiris A, Evereklioglu C, Erkilic K, et al. Intravitreal triamcinolone acetonide for treatment of persistent macular oedema in branch retinal vein occlusion. Eye 2006;20:13-17.
  11. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular oedema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-806.
  12. Chylack LT Jr, Wolfe JK, Singer DM, et al. The Lens Opacities Classification System III. The Longitudinal Study of Cataract Study Group. Arch Ophthalmol 1993;111:831-6.
  13. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 1991;98:766-85.
  14. Chan A, Duker JS. A standardized method for reporting changes in macular thickening using optical coherence tomography. Arch Ophthalmol 2005;123:939-43.
  15. Spandau UH, Derse M, Schmitz-Valckenberg P, et al. Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema. Br J Ophthalmol 2005;89:999-1003.
  16. Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 2000;84:1064-7.
  17. Larsson J, Zhu M, Sutter F, et al. Relation between reduction of foveal thickness and visual acuity in diabetic macular oedema treated with intravitreal triamcinolone. Am J Ophthalmol 2005;139:802-6.
  18. Jonas JB, Degenring RF, Kreissig I, et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005;112:593-8.
  19. Chan CK, Fan DS, Chan WM, et al. Ocular-hypertensive response and corneal endothelial changes after intravitreal triamcinolone injections in Chinese subjects: a 6-month follow-up study. Eye 2005;19:625-30.